NEW YORK (GenomeWeb News) — Ferrer in Code will distribute Agendia’s MammaPrint breast cancer recurrence assay and its CupPrint cancer of unknown primary test in Spain, Agendia said today.
 
Agendia CEO Bernhard Sixt said the partners are currently discussing “future steps in order to intensify the co-operation in other parts of the world.”
 
Ferrer in Code is a subsidiary of the pharmaceutical company Ferrer.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.